NeRRe Therapeutics is a clinical-stage company developing a pipeline of three neurokinin-1 antagonists for the treatment of common, chronic and debilitating conditions caused by neuronal hypersensitivity associated with neurokinin-1 receptor system dysfunction.
|Employees (est.) (Jan 2022)||11|
NeRRe Therapeutics total Funding
NeRRe Therapeutics latest funding size
Time since last funding
|5 years ago|
NeRRe Therapeutics investors
|Advent Venture Partners, Forbion Capital Partners, Fountain Healthcare Partners, Advent Life Sciences, OrbiMed, Novo A/S, GlaxoSmithKline|
|GBP||FY, 2014||FY, 2015||FY, 2016||FY, 2017||FY, 2018|
When was NeRRe Therapeutics founded?
NeRRe Therapeutics was founded in 2012.
Who are NeRRe Therapeutics key executives?
NeRRe Therapeutics's key executives are Andrew Kay, Mary Kerr and Kaasim Mahmood.
How many employees does NeRRe Therapeutics have?
NeRRe Therapeutics has 11 employees.
Who are NeRRe Therapeutics competitors?
Competitors of NeRRe Therapeutics include Genomatica, Arven Ilac and CELLEX.
Where is NeRRe Therapeutics headquarters?
NeRRe Therapeutics headquarters is located at Gunnels Wood Rd, Stevenage.
Where are NeRRe Therapeutics offices?
NeRRe Therapeutics has offices in Stevenage and Hertfordshire.
How many offices does NeRRe Therapeutics have?
NeRRe Therapeutics has 2 offices.
Receive alerts for 300+ data fields across thousands of companies